Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude+Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Organon & Co. Common Stock
(NY:
OGN
)
13.35
+0.03 (+0.23%)
Official Closing Price
Updated: 7:00 PM EDT, May 8, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Organon & Co. Common Stock
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
Halper Sadeh LLC is Investigating Whether HLX, OGN, XOMA, RMAX are Obtaining Fair Deals for their Shareholders
May 06, 2026
From
Halper Sadeh LLC
Via
GlobeNewswire
Halper Sadeh LLC is Investigating Whether SLNO, OGN, RMAX, XOMA are Obtaining Fair Deals for their Shareholders
May 05, 2026
From
Halper Sadeh LLC
Via
GlobeNewswire
Halper Sadeh LLC is Investigating Whether MKC, LEG, OGN, KW are Obtaining Fair Deals for their Shareholders
May 05, 2026
From
Halper Sadeh LLC
Via
GlobeNewswire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: XOMA Royalty Corporation (Nasdaq – XOMA), Organon & Co. (NYSE – OGN), RE/MAX Holdings, Inc. (NYSE – RMAX), Soleno Therapeutics, Inc. (Nasdaq – SLNO)
May 05, 2026
From
Brodsky & Smith LLC
Via
GlobeNewswire
Halper Sadeh LLC is Investigating Whether AVNS, OGN, ESQ, VRE are Obtaining Fair Deals for their Shareholders
May 05, 2026
From
Halper Sadeh LLC
Via
GlobeNewswire
Organon Reports Results for the First Quarter Ended March 31, 2026
April 30, 2026
From
Organon & Co.
Via
Business Wire
Organon Cancels First Quarter Earnings Call
April 29, 2026
From
Organon & Co.
Via
Business Wire
Organon & Co. Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Organon & Co. - OGN
April 28, 2026
From
Kahn Swick & Foti, LLC
Via
Business Wire
Halper Sadeh LLC is Investigating Whether OGN, XOMA, RMAX, SLNO are Obtaining Fair Deals for their Shareholders
April 27, 2026
From
Halper Sadeh LLC
Via
GlobeNewswire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: XOMA Royalty Corporation (Nasdaq – XOMA), Organon & Co. (NYSE – OGN), RE/MAX Holdings, Inc. (NYSE – RMAX), Soleno Therapeutics, Inc. (Nasdaq – SLNO)
April 27, 2026
From
Brodsky & Smith LLC
Via
GlobeNewswire
OGN Stock Alert: Halper Sadeh LLC is Investigating Whether Organon & Co. is Obtaining a Fair Price for its Shareholders
April 27, 2026
From
Halper Sadeh LLC
Via
Business Wire
Sun Pharma signs Definitive Agreement to Acquire Organon
April 26, 2026
From
Organon & Co.
Via
Business Wire
Organon To Report First Quarter 2026 Results and Host Conference Call on May 7, 2026
April 16, 2026
From
Organon & Co.
Via
Business Wire
Organon’s VTAMA® (tapinarof) cream, 1%, Granted Strong Recommendation in the 2026 American Academy of Dermatology Guidelines for Pediatric Atopic Dermatitis
April 15, 2026
From
Organon & Co.
Via
Business Wire
Organon Debuts New Analysis of VTAMA® (tapinarof) cream, 1%, Phase 3 Pooled Data Demonstrating Early and Consistent Skin Clearance and Itch Improvement in Atopic Dermatitis Patients Down to 2 Years of Age
March 27, 2026
From
Organon & Co.
Via
Business Wire
New Analysis of Organon’s VTAMA® (tapinarof) cream, 1%, Phase 3 Data Showed Early and Consistent Improvement in Patient-Reported Sleep Subdomains in Pediatric Patients Down to 2 Years of Age with Atopic Dermatitis
February 27, 2026
From
Organon & Co.
Via
Business Wire
Organon Enters into Agreement to License MIUDELLA®, Sebela Pharmaceuticals’ Hormone-Free Intrauterine Device
February 23, 2026
From
Organon & Co.
Via
Business Wire
Organon Reports Results for the Fourth Quarter and Full Year Ended December 31, 2025
February 12, 2026
From
Organon & Co.
Via
Business Wire
Organon To Report Fourth Quarter and Full Year 2025 Results and Host Conference Call on February 12, 2026
January 29, 2026
From
Organon & Co.
Via
Business Wire
Organon Completes Divestiture of JADA® System to Laborie
January 28, 2026
From
Organon & Co.
Via
Business Wire
Organon Announces US Food and Drug Administration Approval of Supplemental New Drug Application Extending Duration of Use of NEXPLANON® (etonogestrel implant) 68 mg Radiopaque
January 16, 2026
From
Organon & Co.
Via
Business Wire
Organon To Present at the Piper Sandler 37th Annual Healthcare Conference
November 25, 2025
From
Organon & Co.
Via
Business Wire
Henlius and Organon Announce US FDA Approval of POHERDY® (pertuzumab-dpzb), the First PERJETA (pertuzumab) Biosimilar in the US
November 17, 2025
From
Organon & Co.
Via
Business Wire
Organon Investigation Initiated By Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates Claims On Behalf of Investors of Organon & Co. - OGN
November 14, 2025
From
Kahn Swick & Foti, LLC
Via
Business Wire
Organon Reports Results for the Third Quarter Ended September 30, 2025
November 10, 2025
From
Organon & Co.
Via
Business Wire
New Data Show Early and Consistent Response to VTAMA® (tapinarof) Cream, 1%, in Children Aged 2+ with Atopic Dermatitis, Including Those With Associated Comorbidities
November 08, 2025
From
Organon & Co.
Via
Business Wire
Organon Announces Agreement to Divest its JADA® System for Up to $465 Million to Laborie
November 07, 2025
From
Organon & Co.
Via
Business Wire
Organon To Report Third Quarter 2025 Results and Host Conference Call on November 10, 2025
November 06, 2025
From
Organon & Co.
Via
Business Wire
Organon Investigation Initiated By Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates Claims On Behalf of Investors of Organon & Co. - OGN
October 28, 2025
From
Kahn Swick & Foti, LLC
Via
Business Wire
Kaplan Fox is Investigating Organon & Co. (OGN) Following an Announcement of Findings of an Audit Committee Investigation and CEO Resignation
October 27, 2025
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.